-
Sector Analysis
NewChronic Lymphocytic Leukemia (CLL) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Chronic Lymphocytic Leukemia (CLL). These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases. CLL develops from the gradual clonal development and buildup of malignant...
-
Sector Analysis
NewAcute Myeloid Leukemia (AML) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Acute Myeloid Leukemia (AML). These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases. Acute myeloid (or myelogenous or myelocytic) leukemia (AML) is a...
-
Product Insights
NewMyelodysplastic Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
GlobalData's clinical trial report, “Myelodysplastic Syndrome Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update" provides an overview of Myelodysplastic Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Myelodysplastic Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 &...
-
Track & Monitor
NewGenomics in pharma: T-cell culturing
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s T-cell culturing within Genomics innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge and...
-
Track & Monitor
NewImmuno-oncology in pharma: oncolytic viral proteins
Why settle for outdated information when you can stay ahead of the curve with our comprehensive report? Our team of industry experts has meticulously researched and analyzed the latest trends, innovations, and emerging technologies in the pharma industry’s oncolytic viral proteins within Immuno-oncology innovations. By leveraging our report, you'll gain invaluable insights that can revolutionize your business strategies and give you a competitive edge. Why Choose Our Report? Unparalleled Expertise: Our research team consists of seasoned analysts with deep knowledge...
-
Track & Monitor
NewImmuno-oncology in Pharmaceuticals: Cancer chimeric antigen receptor (CAR) T-cell therapy
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Sector Analysis
NewDiffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Diffuse Large B-Cell Lymphoma (DLBCL) Marketed and Pipeline Drugs Report Overview Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL). The subtypes of NHL are defined by the cell of origin, the location involved, and the extensive histopathologic, immunophenotypic, and genetic criteria. B-cell NHLs generally arise in the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen, and can disseminate to distant sites such as the lung or brain in the later...
-
Sector Analysis
Ewing Sarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Ewing Sarcoma Marketed and Pipeline Drugs Report Overview Ewing sarcoma (ES) is an aggressive tumor of adolescents and young adults that constitutes 10% to 15% of all bone sarcomas. The disease is named after James Ewing, who first described it in 1921. These sarcomas originate from unique mesenchymal progenitor cells due to their similar histologic and immunohistochemical characteristics. The most common anatomical sites include the pelvis, axial skeleton, and femur; however, it may occur in almost any bone or soft...
-
Track & Monitor
Key innovators in cancer radiotherapy
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
Renal Cell Carcinoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Renal Cell Carcinoma Clinical Trials Market Report Overview The Renal Cell Carcinoma clinical trial market research report provides an overview of Renal Cell Carcinoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Cell Carcinoma. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points...
-
Product Insights
Multiple Myeloma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Multiple Myeloma Clinical Trial Market Overview The Multiple Myeloma (Kahler Disease) clinical trial market research report provides an overview of Multiple Myeloma (Kahler Disease) Clinical trials scenario. This report provides top line data relating to the clinical trials on Multiple Myeloma (Kahler Disease). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Rhabdomyosarcoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Rhabdomyosarcoma Clinical Trials Market Report Overview The Rhabdomyosarcoma clinical trial market research report an overview of Rhabdomyosarcoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Rhabdomyosarcoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. The report also provides prominent drugs...
-
Product Insights
Muscle Invasive Bladder Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Muscle Invasive Bladder Cancer (MIBC) Clinical Trials Market Report Overview The MIBC clinical trial market research report provides an overview of Muscle Invasive Bladder Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Muscle Invasive Bladder Cancer. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status,...
-
Track & Monitor
Chemotherapy in Pharmaceuticals: Platinum-based cancer drug compositions
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Sector Analysis
Immuno-oncology (IO) – Thematic Intelligence
Accessing the in-depth insight from the ‘Immuno-Oncology Market' report will allow you to – Obtain immuno-oncology market assessment and forecast across multiple regions Gain insight into promising early-stage approaches. Our indication specific forecast models answer questions such as – What is the target patient pool for cell & gene therapies in each cancer indication? Which patient groups are more likely to receive these therapies? What does the cell & gene therapy clinical stage pipeline look like in each cancer indication What...
-
Sector Analysis
Ovarian Cancer – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Ovarian Cancer Cell and Gene Therapy Market Report Overview Ovarian cancer can be broken down into many different types of neoplasms based on specific histopathologic entities and clinical behaviors, and treatment depends on the specific tumor type. Most clinical cases are epithelial ovarian cancers, which represent approximately 90% of diagnosed patients. Ovarian Cancer cell and gene therapy (CGT) market research includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and pipeline therapies...
-
Sector Analysis
Melanoma – Cell and Gene Therapies 15-Market Assessment and Forecast to 2031
Melanoma Cell and Gene Therapy Market Report Overview Melanoma is a malignant neoplasm of melanocytes, the pigment cells in the skin located on the epidermis, the most superficial layer of the skin. While the underlying causes remain unclear, several risk factors that increase the chance of developing melanoma have been identified. Ultraviolet light exposure is considered the leading risk factor for melanoma because UV rays can cause DNA damage to skin cells. The main sources of UV rays are sunlight...
-
Product Insights
Diffuse Large B-Cell Lymphoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Diffuse Large B-Cell Lymphoma Clinical Trials Market Report Overview The Diffuse Large B-Cell Lymphoma clinical trial market research report provides an overview of Diffuse Large B-Cell Lymphoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase,...
-
Sector Analysis
Myelofibrosis Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast to 2031
Myelofibrosis Market Report Overview The Myelofibrosis market size across the 8MM was valued at $2.39 billion in 2021 and is expected to achieve a CAGR of more than 1% during 2021-2031. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). Incyte was the first company to capitalize on the clinical and commercial potential of the MF market with the landmark approval of...
-
Product Insights
Acute Myelocytic Leukemia Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
AML Clinical Trials Market Report Overview The AML clinical trial market research report provides an overview of AML clinical trials scenario. The report provides top-line data relating to the clinical trials on AML. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.